417 related articles for article (PubMed ID: 25773740)
1. Lowering LDL cholesterol is good, but how and in whom?
Stone NJ; Lloyd-Jones DM
N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
[No Abstract] [Full Text] [Related]
2. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
Huynh K
Nat Rev Cardiol; 2015 May; 12(5):261. PubMed ID: 25824512
[No Abstract] [Full Text] [Related]
3. PCSK9 Inhibitors and Cardiovascular Events.
Auer J; Berent R; Primus C
N Engl J Med; 2015 Aug; 373(8):773. PubMed ID: 26287855
[No Abstract] [Full Text] [Related]
4. PCSK9 Inhibitors and Cardiovascular Events.
Robinson JG; Kastelein JJ
N Engl J Med; 2015 Aug; 373(8):774. PubMed ID: 26287854
[No Abstract] [Full Text] [Related]
5. PCSK9 Inhibitors and Cardiovascular Events.
Sabatine MS; Wasserman SM; Stein EA
N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
[No Abstract] [Full Text] [Related]
6. PCSK9 Inhibitors and Cardiovascular Events.
Goemann IM; Londero TM; Dora JM
N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
[No Abstract] [Full Text] [Related]
7. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
Mayor S
BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
[No Abstract] [Full Text] [Related]
8. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
[TBL] [Abstract][Full Text] [Related]
9. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
[No Abstract] [Full Text] [Related]
10. PCSK9 inhibition: the next statin?
Vogel RA
J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
[No Abstract] [Full Text] [Related]
11. Is intensive LDL-cholesterol lowering beneficial and safe?
Cheung BM; Lam KS
Lancet; 2010 Nov; 376(9753):1622-4. PubMed ID: 21067806
[No Abstract] [Full Text] [Related]
12. New Drugs for Lowering LDL-Cholesterol.
Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
[TBL] [Abstract][Full Text] [Related]
13. Further LDL Lowering Could Reduce Cardiovascular Risk.
Mechcatie E; Rosenberg K
Am J Nurs; 2018 Nov; 118(11):55-56. PubMed ID: 30358599
[TBL] [Abstract][Full Text] [Related]
14. Lipid parameters and cardiovascular events in patients taking statins.
Brook RD; Rubenfire M
JAMA; 2012 Jul; 308(2):132; author reply 132-3. PubMed ID: 22782403
[No Abstract] [Full Text] [Related]
15. Lipid parameters and cardiovascular events in patients taking statins.
Martin SS; Jones SR
JAMA; 2012 Jul; 308(2):131-2; author reply 132-3. PubMed ID: 22782402
[No Abstract] [Full Text] [Related]
16. Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.
Sniderman AD; Thanassoulis G
Evid Based Med; 2013 Apr; 18(2):73-4. PubMed ID: 22893654
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
[TBL] [Abstract][Full Text] [Related]
18. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
19. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
20. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
Lloyd-Jones DM
JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
